Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin A Derman

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Geriatric Oncology|November 9, 2020
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patientsBenjamin A Derman, Keriann Kordas, Emily Molloy, et al.
JCO Oncology Practice|April 10, 2026
Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic MalignanciesBenjamin A Derman, James H Essell, Mustafa S Ascha, et al.
Blood Advances|November 15, 2019
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adultsBenjamin A Derman, Keriann Kordas, Jean Ridgeway, et al.
Science Translational Medicine|May 27, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myelomaAdam S Sperling, Benjamin A Derman, Sarah Nikiforow, et al.
Cancer Immunology Research|January 21, 2026
Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy bb21217 for relapsed and refractory multiple myeloma: results from the phase 1 CRB-402 studyMelissa Alsina, Nina Shah, Sundar Jagannath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Blood|August 1, 2020
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myelomaJagoda K Jasielec, Tadeusz Kubicki, Noopur Raje, et al.
British Journal of Haematology|September 10, 2023
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trialTadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel, et al.
Blood|May 7, 2024
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myelomaTadeusz Kubicki, Dominik Dytfeld, David Barnidge, et al.
The Lancet. Oncology|January 15, 2023
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trialDominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Geriatric Oncology|November 9, 2020
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patientsBenjamin A Derman, Keriann Kordas, Emily Molloy, et al.
JCO Oncology Practice|April 10, 2026
Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic MalignanciesBenjamin A Derman, James H Essell, Mustafa S Ascha, et al.
Blood Advances|November 15, 2019
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adultsBenjamin A Derman, Keriann Kordas, Jean Ridgeway, et al.
Science Translational Medicine|May 27, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myelomaAdam S Sperling, Benjamin A Derman, Sarah Nikiforow, et al.
Cancer Immunology Research|January 21, 2026
Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy bb21217 for relapsed and refractory multiple myeloma: results from the phase 1 CRB-402 studyMelissa Alsina, Nina Shah, Sundar Jagannath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2026
Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living GuidelineLisa K Hicks, Hans J Messersmith, Samer Al Hadidi, et al.
Blood|August 1, 2020
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myelomaJagoda K Jasielec, Tadeusz Kubicki, Noopur Raje, et al.
British Journal of Haematology|September 10, 2023
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trialTadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel, et al.
Blood|May 7, 2024
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myelomaTadeusz Kubicki, Dominik Dytfeld, David Barnidge, et al.
The Lancet. Oncology|January 15, 2023
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trialDominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, et al.
Pageof 6